
## Magdalena Krintus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8439165/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1657-65.	1.4	117
2	Critical appraisal of inflammatory markers in cardiovascular risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 263-279.	2.7	67
3	High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 143-172.	2.7	51
4	Defining normality in a European multinational cohort: Critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. International Journal of Cardiology, 2015, 187, 256-263.	0.8	41
5	25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clinical Biochemistry, 2012, 45, 1568-1572.	0.8	30
6	Left ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1–3. Renal Failure, 2015, 37, 1105-1110.	0.8	28
7	Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. European Journal of Clinical Investigation, 2011, 41, 667-671.	1.7	23
8	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1161-1168.	1.4	23
9	Serum Inhibin A and Inhibin B Levels in Epithelial Ovarian Cancer Patients. PLoS ONE, 2014, 9, e90575.	1.1	21
10	Value of C-Reactive Protein as a Risk Factor for Acute Coronary Syndrome: A Comparison with Apolipoprotein Concentrations and Lipid Profile. Mediators of Inflammation, 2012, 2012, 1-10.	1.4	19
11	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clinical Biochemistry, 2017, 50, 599-604.	0.8	14
12	Traceability validation of six enzyme measurements on the Abbott Alinity c analytical system. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1250-1256.	1.4	14
13	How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes. Journal of Medical Biochemistry, 2011, 30, 237-243.	0.7	13
14	A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1035-1043.	1.4	13
15	Effect of second and third generation oral contraceptives on C-reactive protein, lipids and apolipoproteins in young, non-obese, non-smoking apparently healthy women. Clinical Biochemistry, 2010, 43, 626-628.	0.8	12
16	Laboratory-related issues in the measurement of cardiac troponins with highly sensitive assays. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1773-1783.	1.4	11
17	Association between Fasting Glucose Concentration, Lipid Profile and 25(OH)D Status in Children Aged 9–11. Nutrients, 2018, 10, 1359.	1.7	10
18	The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes. Journal of Medical Biochemistry, 2009, 28, 293-299.	0.7	9

#	Article	IF	CITATIONS
19	A-FABP and its association with atherogenic risk profile and insulin resistance in young overweight and obese women. Biomarkers in Medicine, 2013, 7, 723-730.	0.6	8
20	Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. BMJ Open, 2017, 7, e013218.	0.8	8
21	25-Hydroxyvitamin D, biomarkers of eosinophilic inflammation, and airway remodeling in children with newly diagnosed untreated asthma. Allergy and Asthma Proceedings, 2017, 38, 29-36.	1.0	8
22	Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I. Clinica Chimica Acta, 2016, 462, 193-200.	0.5	7
23	Non-fasting lipid profile determination in presumably healthy children: Impact on the assessment of lipid abnormalities. PLoS ONE, 2018, 13, e0198433.	1.1	7
24	Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals. British Journal of Biomedical Science, 2019, 76, 190-194.	1.2	7
25	Gamma-glutamyltransferase activity as a surrogate biomarker of metabolic health status in young nondiabetic obese women. Biomarkers in Medicine, 2017, 11, 449-457.	0.6	6
26	Effect of fasting hyperglycemia and insulin resistance on bone turnover markers in children aged 9–11Âyears. Journal of Diabetes and Its Complications, 2021, 35, 108000.	1.2	6
27	Relationships between Bone Turnover Markers and Factors Associated with Metabolic Syndrome in Prepubertal Cirls and Boys. Nutrients, 2022, 14, 1205.	1.7	6
28	Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer. International Journal of Endocrinology, 2013, 2013, 1-6.	0.6	5
29	Chosen Vascular Risk Markers in Pseudoexfoliation Syndrome: An Age-Related Disorder. Journal of Ophthalmology, 2017, 2017, 1-4.	0.6	5
30	Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity. Nutrients, 2021, 13, 4339.	1.7	5
31	The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials, 2017, 18, 316.	0.7	4
32	Analytical Performance of 10 High-Volume Clinical Chemistry Assays on the Alinity c System. Laboratory Medicine, 2019, 50, e1-e8.	0.8	4
33	Serum ANGPTL8 and ANGPTL3 as Predictors of Triglyceride Elevation in Adult Women. Metabolites, 2022, 12, 539.	1.3	3
34	Improving clinical laboratory performance through quality indicators. Clinical Biochemistry, 2017, 50, 547-549.	0.8	2
35	Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results. Cardiology Journal, 2021, 28, 58-66.	0.5	2
36	Serum 25(OH)D status and lipid profile in children with newly diagnosed asthma. Medical Research Journal, 2015, 3, 113-116.	0.1	1